Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-23

Vertex Pharmaceuticals Inc (VRTX)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$21,144,261
Reshma Kewalramani total, FY2025
30th
CEO pay percentile vs peers
80:1
CEO-to-median pay ratio
93.47%
Say-on-pay support, latest vote
Companies that benchmark against VRTX
20 companies name VRTX as a compensation peer

Each company listed discloses VRTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VRTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Reshma Kewalramani$1,600,000$0$15,002,270$0$4,118,640$0$423,351$21,144,261
Chief Executive Officer and President
Stuart Arbuckle521,48609,341,927000132,9349,996,347
Former Executive Vice President, Chief Operating Officer
Charles Wagner974,80805,250,81701,965,000051,1848,241,809
Executive Vice President, Chief Operating and Financial Officer
Nia Tatsis750,00004,900,52201,282,163042,2356,974,920
Executive Vice President, Chief Regulatory and Quality Officer
Amit Sachdev700,00004,900,52201,155,420021,3016,777,243
Executive Vice President, Chief Patient and External Affairs Officer
Carmen Bozic835,00004,375,53101,378,251057,5396,646,321
Executive Vice President, Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Reshma Kewalramani$21,144,261$21,538,668$20,594,441−394,407
Stuart Arbuckle9,996,3479,383,4638,998,949+612,884
Charles Wagner8,241,8097,999,4407,371,751+242,369
Nia Tatsis6,974,9207,334,316−359,396
Amit Sachdev6,777,243
Carmen Bozic6,646,321

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Bruce I. SachsDirector2026-04-15A107.35$443$47,500Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayDirector2026-04-15A80.5144335,625Derivative, Class A CommonForm 4 ↗
Alan GarberDirector2026-04-15A33.944315,000Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayDirector2026-05-01A796Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-05-014,2993 insiders, 3 accrual rows
Diana McKenzieDirector2026-05-01A94300CommonForm 4 ↗
Diana McKenzieDirector2026-05-01D796CommonForm 4 ↗
Nancy ThornberryDirector2026-05-01D398CommonForm 4 ↗
Suketu UpadhyayDirector2026-05-01A2,86600Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayDirector2026-05-01D796CommonForm 4 ↗
Bruce I. SachsDirector2026-05-01A2,86600Derivative, Class A CommonForm 4 ↗
Lloyd CarneyDirector2026-05-01A2,86600Derivative, Class A CommonForm 4 ↗
Jennifer SchneiderDirector2026-05-01A47200CommonForm 4 ↗
Jennifer SchneiderDirector2026-05-01D796CommonForm 4 ↗
Jennifer SchneiderDirector2026-05-01A796Derivative, Class A CommonForm 4 ↗
Sangeeta N. BhatiaDirector2026-05-01A94300CommonForm 4 ↗
Diana McKenzieDirector2026-05-01A796Derivative, Class A CommonForm 4 ↗
Alan GarberDirector2026-05-01A47200CommonForm 4 ↗
Sangeeta N. BhatiaDirector2026-05-01D318424134,746CommonForm 4 ↗
Joy LiuEVP and Chief Legal Officer2026-05-01D1,104425469,222CommonForm 4 ↗
Nancy ThornberryDirector2026-05-01A398Derivative, Class A CommonForm 4 ↗
Nancy ThornberryDirector2026-05-01A47200CommonForm 4 ↗
Michel LagardeDirector2026-05-01A2,86600Derivative, Class A CommonForm 4 ↗
Carmen BozicEVP and CMO2026-05-12D6,9884503,144,600CommonForm 4 ↗
Mark E. BunnageEVP, Chief Scientific Officer2026-05-15D3345314,964CommonForm 4 ↗
Carmen BozicEVP and CMO2026-05-15D1,354453613,971CommonForm 4 ↗
Carmen BozicEVP and CMO2026-05-29D1,974450888,300CommonForm 4 ↗
Joy LiuEVP and Chief Legal Officer2026-06-01D828440364,245CommonForm 4 ↗
Carmen BozicEVP and CMO2026-06-05D1,745450785,250CommonForm 4 ↗
Carmen BozicEVP and CMO2026-06-15D4,0624501,827,900CommonForm 4 ↗
Carmen BozicEVP and CMO2026-06-18D1,020462471,413CommonForm 4 ↗
Carmen BozicEVP and CMO2026-06-26D596483287,570CommonForm 4 ↗
Joy LiuEVP and Chief Legal Officer2026-07-01D828503416,244CommonForm 4 ↗
Duncan McKechnieEVP, Chief Commercial Officer2026-07-02D1,541519799,779CommonForm 4 ↗
Nia TatsisEVP, Chief Reg. & Quality Off.2026-07-02D1,500525787,485CommonForm 4 ↗
Alan GarberDirector2026-07-15A31.5647515,000Derivative, Class A CommonForm 4 ↗
Bruce I. SachsDirector2026-07-15A99.9447547,500Derivative, Class A CommonForm 4 ↗
Nia TatsisEVP, Chief Reg. & Quality Off.2026-07-21A8,25100CommonForm 4 ↗
Amit SachdevEVP Chief Patient & Ext Af Off2026-07-21A8,25100CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 41 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Bruce I. SachsDirector2026-04-15A107.35$443$47,500Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayDirector2026-04-15A80.5144335,625Derivative, Class A CommonForm 4 ↗
Alan GarberDirector2026-04-15A33.944315,000Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayDirector2026-05-01A796Derivative, Class A CommonForm 4 ↗
Jennifer SchneiderDirector2026-05-01A1,43300Derivative, Class A CommonForm 4 ↗
Diana McKenzieDirector2026-05-01A94300CommonForm 4 ↗
Diana McKenzieDirector2026-05-01D796CommonForm 4 ↗
Nancy ThornberryDirector2026-05-01D398CommonForm 4 ↗
Suketu UpadhyayDirector2026-05-01A2,86600Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayDirector2026-05-01D796CommonForm 4 ↗
Bruce I. SachsDirector2026-05-01A2,86600Derivative, Class A CommonForm 4 ↗
Alan GarberDirector2026-05-01A1,43300Derivative, Class A CommonForm 4 ↗
Lloyd CarneyDirector2026-05-01A2,86600Derivative, Class A CommonForm 4 ↗
Jennifer SchneiderDirector2026-05-01A47200CommonForm 4 ↗
Jennifer SchneiderDirector2026-05-01D796CommonForm 4 ↗
Jennifer SchneiderDirector2026-05-01A796Derivative, Class A CommonForm 4 ↗
Sangeeta N. BhatiaDirector2026-05-01A94300CommonForm 4 ↗
Nancy ThornberryDirector2026-05-01A1,43300Derivative, Class A CommonForm 4 ↗
Diana McKenzieDirector2026-05-01A796Derivative, Class A CommonForm 4 ↗
Alan GarberDirector2026-05-01A47200CommonForm 4 ↗
Sangeeta N. BhatiaDirector2026-05-01D318424134,746CommonForm 4 ↗
Joy LiuEVP and Chief Legal Officer2026-05-01D1,104425469,222CommonForm 4 ↗
Nancy ThornberryDirector2026-05-01A398Derivative, Class A CommonForm 4 ↗
Nancy ThornberryDirector2026-05-01A47200CommonForm 4 ↗
Michel LagardeDirector2026-05-01A2,86600Derivative, Class A CommonForm 4 ↗
Carmen BozicEVP and CMO2026-05-12D6,9884503,144,600CommonForm 4 ↗
Mark E. BunnageEVP, Chief Scientific Officer2026-05-15D3345314,964CommonForm 4 ↗
Carmen BozicEVP and CMO2026-05-15D1,354453613,971CommonForm 4 ↗
Carmen BozicEVP and CMO2026-05-29D1,974450888,300CommonForm 4 ↗
Joy LiuEVP and Chief Legal Officer2026-06-01D828440364,245CommonForm 4 ↗
Carmen BozicEVP and CMO2026-06-05D1,745450785,250CommonForm 4 ↗
Carmen BozicEVP and CMO2026-06-15D4,0624501,827,900CommonForm 4 ↗
Carmen BozicEVP and CMO2026-06-18D1,020462471,413CommonForm 4 ↗
Carmen BozicEVP and CMO2026-06-26D596483287,570CommonForm 4 ↗
Joy LiuEVP and Chief Legal Officer2026-07-01D828503416,244CommonForm 4 ↗
Duncan McKechnieEVP, Chief Commercial Officer2026-07-02D1,541519799,779CommonForm 4 ↗
Nia TatsisEVP, Chief Reg. & Quality Off.2026-07-02D1,500525787,485CommonForm 4 ↗
Alan GarberDirector2026-07-15A31.5647515,000Derivative, Class A CommonForm 4 ↗
Bruce I. SachsDirector2026-07-15A99.9447547,500Derivative, Class A CommonForm 4 ↗
Nia TatsisEVP, Chief Reg. & Quality Off.2026-07-21A8,25100CommonForm 4 ↗
Amit SachdevEVP Chief Patient & Ext Af Off2026-07-21A8,25100CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Charles WagnerPSU2025-02-123,328$750,181
Stuart ArbucklePSU2025-02-123,9521,781,680
Amit SachdevPSU2025-02-123,1061,400,278
Nia TatsisRSU2025-02-126,2112,800,105
Charles WagnerRSU2025-02-126,6553,000,274
Stuart ArbucklePSU2025-02-127,9033,106,498
Amit SachdevRSU2025-02-126,2112,800,105
Nia TatsisPSU2025-02-123,1061,400,278
Reshma KewalramaniRSU2025-02-1219,0158,572,532
Amit SachdevPSU2025-02-123,106700,139
Charles WagnerPSU2025-02-123,3281,500,362
Stuart ArbucklePSU2025-02-123,952890,840
Carmen BozicPSU2025-02-122,773625,076
Nia TatsisPSU2025-02-123,106700,139
Carmen BozicPSU2025-02-122,7731,250,152
Stuart ArbuckleRSU2025-02-127,9033,562,909
Reshma KewalramaniPSU2025-02-129,5084,286,492
Reshma KewalramaniPSU2025-02-129,5082,143,246
Carmen BozicRSU2025-02-125,5462,500,303
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Charles Wagner$3,000,274$2,250,543$042.9%
Stuart Arbuckle3,562,9095,779,018061.9%
Amit Sachdev2,800,1052,100,417042.9%
Nia Tatsis2,800,1052,100,417042.9%
Reshma Kewalramani8,572,5326,429,738042.9%
Carmen Bozic2,500,3031,875,228042.9%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Stuart ArbuckleRSU7,904$3,583,357
Charles WagnerRSU6,6563,017,564
Nia TatsisRSU6,2122,816,272
Amit SachdevRSU6,2122,816,272
Carmen BozicRSU3,9521,791,679
Nia TatsisRSU2,6221,188,710
Charles WagnerRSU7,1143,225,203
Amit SachdevRSU7,8663,566,130
Nia TatsisRSU7,8663,566,130
Amit SachdevRSU4,7442,150,740
Nia TatsisRSU7,1143,225,203
Nia TatsisRSU4,7442,150,740
Amit SachdevRSU4,7432,150,286
Carmen BozicRSU2,6221,188,710
Reshma KewalramaniRSU8,9914,076,160
Stuart ArbuckleRSU4,9402,239,598
Charles WagnerRSU9,4404,279,718
Carmen BozicRSU5,9282,687,518
Amit SachdevRSU3,8831,760,397
Nia TatsisRSU3,8831,760,397
Carmen BozicRSU3,4661,571,346
Nia TatsisRSU6,2112,815,819
Charles WagnerRSU6,6553,017,111
Charles WagnerRSU3,1471,426,724
Carmen BozicRSU7,8663,566,130
Charles WagnerRSU4,7432,150,286
Amit SachdevRSU7,1143,225,203
Reshma KewalramaniRSU26,97212,228,026
Reshma KewalramaniRSU20,3289,215,902
Reshma KewalramaniRSU19,0168,621,094
Reshma KewalramaniRSU19,0158,620,640
Reshma KewalramaniRSU13,5526,143,935
Reshma KewalramaniRSU11,8855,388,184
Stuart ArbuckleRSU11,2105,082,166
Reshma KewalramaniRSU8,9924,076,613
Stuart ArbuckleRSU8,4483,829,985
Amit SachdevRSU6,2112,815,819
Carmen BozicRSU5,5462,514,335
Charles WagnerRSU4,7442,150,740
Charles WagnerRSU4,1601,885,978
Charles WagnerRSU3,1481,427,177
Amit SachdevRSU2,6221,188,710
Nia TatsisRSU4,7432,150,286
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is intended to align executive compensation with the company's short- and long-term performance and to provide the compensation and incentives required to attract, motivate and retain our high-caliber executives who are crucial to Vertex's long-term success.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultant
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingfalse
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-13207,918,84314,522,776556,01793.47%Passed
20252025-05-14208,886,38617,048,300307,55092.45%Passed
20242024-05-15202,098,57519,223,784875,76091.31%Passed
20232023-05-17200,867,11623,641,105155,57989.47%Passed
20222022-05-18202,178,84916,105,5041,699,41892.62%Passed
20212021-05-19200,764,72218,817,126176,47891.43%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1393.47%a
20252025-05-1492.45%b
20242024-05-1591.31%c

a. Approved under the standard stated in the filing — “3: Advisory Vote to Approve Named Executive Officer Compensation To be approved, this proposal must receive an affirmative vote from shareholders present personally or represented by proxy at the annual meeting representing a majority of the votes cast on the proposal.”.

b. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.

c. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)80 : 1
CEO total compensation$21,144,261
Median employee compensation$264,487
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Bruce I. SachsIndependent · Lead Independent Director · Management Development and Compensation (Chair) · Corporate Governance and Nominating$190,000$400,130$0$25,000$615,130
Suketu UpadhyayIndependent · Audit and Finance (Chair) · Management Development and Compensation142,500400,364023,000565,864
Lloyd CarneyIndependent · Corporate Governance and Nominating (Chair) · Audit and Finance140,000400,364025,000565,364
Sangeeta N. BhatiaIndependent · Science and Technology (Chair) · Corporate Governance and Nominating135,000400,364025,000560,364
Diana McKenzieIndependent · Audit and Finance · Management Development and Compensation127,500400,364025,000552,864
Alan GarberIndependent · Corporate Governance and Nominating · Science and Technology120,000200,182200,065025,000545,247
Michel LagardeIndependent · Audit and Finance115,000400,130025,000540,130
Jennifer SchneiderIndependent · Management Development and Compensation112,500400,364025,000537,864
Nancy ThornberryIndependent · Science and Technology110,000200,182200,065018,000528,247
Jeffrey LeidenEmployee director · Board Chair00000
Reshma KewalramaniEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$100,000
Annual equity retainer$400,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)30,000 / 25,000 / 25,000
Stock ownership guideline5x annual cash retainer ($500,000)
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,192,500
Equity awards (grant-date value)$2,402,184
All other compensation$216,000
Total cost of the board$3,810,684

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Vertex Pharmaceuticals Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Vertex Pharmaceuticals Inc.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Eli Lilly and Company2025David Ricks$1,700,000$23,325,000$0$6,485,500$36,698,337
2AbbVie Inc.2025Robert Michael1,700,00013,268,4563,199,1545,200,00032,530,984
3Incyte Corporation2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
4Gilead Sciences, Inc.2025Daniel O'Day1,795,19215,238,4024,500,0604,848,12028,437,198
5Amgen, Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
6Biogen, Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
7Bristol-Myers Squibb Company2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
8Vertex Pharmaceuticals Inc2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
9Moderna, Inc.2025Stéphane Bancel1,677,7396,897,4556,897,4254,302,36019,932,217
10Jazz Pharmaceuticals plc2025Renee Gala1,003,26916,138,43301,980,00019,151,558
11Regeneron Pharmaceuticals, Inc.2025Leonard Schleifer1,979,922003,682,6557,280,549

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Vertex Pharmaceuticals Incnot disclosedPSU 55 · RSU 45Nonot disclosed
AbbVie Inc.not disclosedPSU 40 · RSU 40 · Options 20Yes — Relative TSRSemler Brossy
Amgen, Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
Biogen, Inc.127%PSU 60 · RSU 40YesPay Governance
Bristol-Myers Squibb Company157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
Eli Lilly and Company218%PSU 100NoFW Cook
Gilead Sciences, Inc.180%PSU 50 · Options 25 · RSU 25Yes — Relative TSRFW Cook
Incyte Corporation138.6%PSU 60 · Options 20 · RSU 20Yes — relative total shareholder return (TSR)Aon
Jazz Pharmaceuticals plc150%PSU 50 · RSU 50Yes — Relative TSRAon
Moderna, Inc.170%PSU 50 · Options 50NoPay Governance LLC
Regeneron Pharmaceuticals, Inc.155%Options 60 · RSA 40not disclosedPay Governance LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Vertex Pharmaceuticals Inc in fiscal 2025?
As disclosed, the highest-paid executive at Vertex Pharmaceuticals Inc in fiscal 2025 was Reshma Kewalramani, who served as Chief Executive Officer and President with total compensation of $21,144,261.
How does Vertex Pharmaceuticals Inc's chief executive pay compare to its disclosed peer group?
The filing shows that Vertex Pharmaceuticals Inc's chief executive pay falls at the 30th percentile of its disclosed peer group.
What is Vertex Pharmaceuticals Inc's CEO-to-median employee pay ratio?
The company reported a CEO-to-median employee pay ratio of 80:1 for fiscal 2025.
How did shareholders vote on Vertex Pharmaceuticals Inc's executive compensation?
As disclosed, shareholders supported the latest executive compensation proposal with 93.47% of votes cast in favor.
How much does Vertex Pharmaceuticals Inc spend in total on board compensation for fiscal 2025?
The filing shows that Vertex Pharmaceuticals Inc spent $3,810,684 in total on board compensation for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Reshma KewalramaniDEF 14A2026-04-020000875320-26-000153Section “Summary Compensation Table”. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809
2Section 01, Stuart ArbuckleDEF 14A2026-04-020000875320-26-000153Section “Summary Compensation Table”. As printed: 9,996,347. Filing ↗machine: r17 · c13 · span 3009011–3009020
3Section 01, Charles WagnerDEF 14A2026-04-020000875320-26-000153Section “Summary Compensation Table”. As printed: 8,241,809. Filing ↗machine: r5 · c13 · span 2960152–2960161
4Section 01, Nia TatsisDEF 14A2026-04-020000875320-26-000153Section “Summary Compensation Table”. As printed: 6,974,920. Filing ↗machine: r14 · c13 · span 2995547–2995556
5Section 01, Amit SachdevDEF 14A2026-04-020000875320-26-000153Section “Summary Compensation Table”. As printed: 6,777,243. Filing ↗machine: r11 · c13 · span 2986647–2986656
6Section 01, Carmen BozicDEF 14A2026-04-020000875320-26-000153Section “Summary Compensation Table”. As printed: 6,646,321. Filing ↗machine: r8 · c13 · span 2977791–2977800
7Section 03, Charles Wagner PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r9 · c14 · span 3212214–3212221
8Section 03, Stuart Arbuckle PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r24 · c14 · span 3276206–3276215
9Section 03, Amit Sachdev PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r16 · c10 · span 3240223–3240228
10Section 03, Nia Tatsis RSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t114 · r6 · c2 · span 1693486–1693491
11Section 03, Charles Wagner RSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r10 · c14 · span 3215992–3216001
12Section 03, Stuart Arbuckle PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r27 · c14 · span 3286833–3286842
13Section 03, Amit Sachdev RSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t114 · r5 · c2 · span 1691296–1691301
14Section 03, Nia Tatsis PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r20 · c10 · span 3256970–3256975
15Section 03, Reshma Kewalramani RSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t114 · r2 · c2 · span 1684221–1684227
16Section 03, Amit Sachdev PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r16 · c10 · span 3240223–3240228
17Section 03, Charles Wagner PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r8 · c14 · span 3207669–3207678
18Section 03, Stuart Arbuckle PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r25 · c14 · span 3280751–3280758
19Section 03, Carmen Bozic PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r12 · c10 · span 3223474–3223479
20Section 03, Nia Tatsis PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r20 · c10 · span 3256970–3256975
21Section 03, Carmen Bozic PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r12 · c10 · span 3223474–3223479
22Section 03, Stuart Arbuckle RSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r26 · c14 · span 3284049–3284058
23Section 03, Reshma Kewalramani PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r4 · c10 · span 3188421–3188426
24Section 03, Reshma Kewalramani PSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t199 · r4 · c10 · span 3188421–3188426
25Section 03, Carmen Bozic RSUDEF 14A2026-04-020000875320-26-000153Section “Grants of Plan-Based Awards During” · grants of plan-based awards table. Filing ↗machine: t114 · r4 · c2 · span 1689118–1689123
26Section 07, pay ratioDEF 14A2026-04-020000875320-26-000153Section “CEO Pay Ratio”. As printed: 80 : 1. Filing ↗machine: t37 · r4 · c9 · span 509518–509520
27Section 08, Bruce I. SachsDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 615,130. Filing ↗machine: t87 · r7 · c10 · span 1229939–1229946
28Section 08, Suketu UpadhyayDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 565,864. Filing ↗machine: t87 · r10 · c10 · span 1243718–1243725
29Section 08, Lloyd CarneyDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 565,364. Filing ↗machine: t87 · r3 · c10 · span 1212149–1212156
30Section 08, Sangeeta N. BhatiaDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 560,364. Filing ↗machine: t87 · r2 · c10 · span 1207754–1207761
31Section 08, Diana McKenzieDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 552,864. Filing ↗machine: t87 · r6 · c10 · span 1225336–1225343
32Section 08, Alan GarberDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 545,247. Filing ↗machine: t87 · r4 · c10 · span 1216548–1216555
33Section 08, Michel LagardeDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 540,130. Filing ↗machine: t87 · r5 · c10 · span 1220933–1220940
34Section 08, Jennifer SchneiderDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 537,864. Filing ↗machine: t87 · r8 · c10 · span 1234346–1234353
35Section 08, Nancy ThornberryDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 528,247. Filing ↗machine: t87 · r9 · c10 · span 1238738–1238745
36Section 08, Jeffrey LeidenDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 0. Filing ↗
37Section 08, Reshma KewalramaniDEF 14A2026-04-020000875320-26-000153Section “Director Compensation”. As printed: 0. Filing ↗
38Section 02, Bruce I. Sachs 2026-04-15Form 42026-04-170000875320-26-000161Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Suketu Upadhyay 2026-04-15Form 42026-04-170000875320-26-000163Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Alan Garber 2026-04-15Form 42026-04-170000875320-26-000159Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Suketu Upadhyay 2026-05-01Form 42026-05-050000875320-26-000193Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Jennifer Schneider 2026-05-01Form 42026-05-050000875320-26-000189Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Diana McKenzie 2026-05-01Form 42026-05-050000875320-26-000185Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Diana McKenzie 2026-05-01Form 42026-05-050000875320-26-000185Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Nancy Thornberry 2026-05-01Form 42026-05-050000875320-26-000191Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Suketu Upadhyay 2026-05-01Form 42026-05-050000875320-26-000193Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Suketu Upadhyay 2026-05-01Form 42026-05-050000875320-26-000193Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Bruce I. Sachs 2026-05-01Form 42026-05-050000875320-26-000187Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Alan Garber 2026-05-01Form 42026-05-050000875320-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Lloyd Carney 2026-05-01Form 42026-05-050000875320-26-000177Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Jennifer Schneider 2026-05-01Form 42026-05-050000875320-26-000189Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Jennifer Schneider 2026-05-01Form 42026-05-050000875320-26-000189Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Jennifer Schneider 2026-05-01Form 42026-05-050000875320-26-000189Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Sangeeta N. Bhatia 2026-05-01Form 42026-05-050000875320-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Nancy Thornberry 2026-05-01Form 42026-05-050000875320-26-000191Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Diana McKenzie 2026-05-01Form 42026-05-050000875320-26-000185Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Alan Garber 2026-05-01Form 42026-05-050000875320-26-000179Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Sangeeta N. Bhatia 2026-05-01Form 42026-05-050000875320-26-000175Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Joy Liu 2026-05-01Form 42026-05-050000875320-26-000183Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Nancy Thornberry 2026-05-01Form 42026-05-050000875320-26-000191Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Nancy Thornberry 2026-05-01Form 42026-05-050000875320-26-000191Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Michel Lagarde 2026-05-01Form 42026-05-050000875320-26-000181Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Carmen Bozic 2026-05-12Form 42026-05-140000875320-26-000222Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Mark E. Bunnage 2026-05-15Form 42026-05-190000875320-26-000226Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Carmen Bozic 2026-05-15Form 42026-05-190000875320-26-000225Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Carmen Bozic 2026-05-29Form 42026-06-020000875320-26-000228Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Joy Liu 2026-06-01Form 42026-06-030000875320-26-000230Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Carmen Bozic 2026-06-05Form 42026-06-090000875320-26-000233Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Carmen Bozic 2026-06-15Form 42026-06-170000875320-26-000235Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Carmen Bozic 2026-06-18Form 42026-06-230000875320-26-000237Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Carmen Bozic 2026-06-26Form 42026-06-300000875320-26-000239Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Joy Liu 2026-07-01Form 42026-07-060000875320-26-000241Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Duncan McKechnie 2026-07-02Form 42026-07-070000875320-26-000243Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Nia Tatsis 2026-07-02Form 42026-07-070000875320-26-000245Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Alan Garber 2026-07-15Form 42026-07-170000875320-26-000247Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Bruce I. Sachs 2026-07-15Form 42026-07-170000875320-26-000249Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Nia Tatsis 2026-07-21Form 42026-07-230000875320-26-000253Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Amit Sachdev 2026-07-21Form 42026-07-230000875320-26-000251Insider equity transaction reported since the proxy statement. Filing ↗
79Section 06, 2026 voteForm 8-K2026-05-130000875320-26-000204Item 5.07 · say-on-pay result. As reported: 93.47% (votes for as printed: 207,918,843). Filing ↗
80Section 06, 2025 voteForm 8-K2025-05-140000875320-25-000194Item 5.07 · say-on-pay result. As reported: 92.45% (votes for as printed: 208,886,386). Filing ↗
81Section 06, 2024 voteForm 8-K2024-05-150000875320-24-000142Item 5.07 · say-on-pay result. As reported: 91.31% (votes for as printed: 202,098,575). Filing ↗
82Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
83Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
84Section 09b board cost (computed)ComputedcomputedCash 1,192,500 + equity 2,402,184 + all other 216,000 = 3,810,684, summed across the director compensation table rows.machine: formula: Σ = 3,810,684
85Eli Lilly and Company, Section 10b CEO totalDEF 14A2026-03-200000059478-26-000029CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024
86AbbVie Inc., Section 10b CEO totalDEF 14A2026-03-230001104659-26-033387CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. Filing ↗machine: t210 · r9 · c26 · span 1414083–1414093
87Incyte Corporation, Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
88Gilead Sciences, Inc., Section 10b CEO totalDEF 14A2026-03-200001308179-26-000106CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
89Amgen, Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen, Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
90Biogen, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in Biogen, Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
91Bristol-Myers Squibb Company, Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
92Vertex Pharmaceuticals Inc (subject), Section 10b CEO totalDEF 14A2026-04-020000875320-26-000153CEO total compensation as printed in Vertex Pharmaceuticals Inc's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809
93Moderna, Inc., Section 10b CEO totalDEF 14A2026-03-160001308179-26-000081CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898
94Jazz Pharmaceuticals plc, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
95Regeneron Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001308179-26-000340CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989
96Section 10a, Regeneron Pharmaceuticals, Inc. reciprocityDEF 14A0001308179-26-000340Regeneron Pharmaceuticals, Inc. names Vertex Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
97Section 10a, Moderna, Inc. reciprocityDEF 14A0001308179-26-000081Moderna, Inc. names Vertex Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
98Section 10a, AbbVie Inc. reciprocityDEF 14A0001104659-26-033387AbbVie Inc.'s most recent proxy was read; its disclosed peer group does not include Vertex Pharmaceuticals Inc. Filing ↗
99Section 10a, Bristol-Myers Squibb Company reciprocityDEF 14A0000014272-26-000006Bristol-Myers Squibb Company's most recent proxy was read; its disclosed peer group does not include Vertex Pharmaceuticals Inc. Filing ↗
100Section 10a, Amgen, Inc. reciprocityDEF 14A0001193125-26-145588Amgen, Inc. names Vertex Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
101Section 10a, Eli Lilly and Company reciprocityDEF 14A0000059478-26-000029Eli Lilly and Company's most recent proxy was read; its disclosed peer group does not include Vertex Pharmaceuticals Inc. Filing ↗
102Section 10a, Gilead Sciences, Inc. reciprocityDEF 14A0001308179-26-000106Gilead Sciences, Inc. names Vertex Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
103Section 10a, Jazz Pharmaceuticals plc reciprocityDEF 14A0001232524-26-000029Jazz Pharmaceuticals plc names Vertex Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗